Migraine Clinical Trial
— REFORMOfficial title:
Registry for Migraine - Structural and Functional Magnetic Resonance Imaging Before and After Erenumab Treatment
This study aims to investigate structural and functional cerebral changes using magnetic resonance imaging before and after treatment with erenumab in patients with migraine.
Status | Recruiting |
Enrollment | 250 |
Est. completion date | July 22, 2025 |
Est. primary completion date | July 22, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Criteria: Inclusion Criteria: - Subject has provided informed consent prior to initiation of any study-specific activities/procedures - Age greater than or equal to 18 years upon entry into screening - History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the International Headache Society (IHS) Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018) based on medical records and/or patient self report - Greater than or equal to 4 headache days that meet criteria as migraine days per month on average across the 3 months before screening after baseline period - Must have demonstrated greater than or equal to 75% compliance in headache diary usage during baseline period Exclusion Criteria: Subjects are excluded from the study if any of the following criteria apply: Disease Related - Greater than 50 years of age at migraine onset - History of cluster headache or hemiplegic migraine headache - Inability to differentiate between migraine from other headaches - The subject is at risk of self-harm or harm to others as evidenced by past suicidal behaviour - History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion Prior/Concomitant Therapy - Previously received erenumab (AimovigĀ®) - Received an anti-CGRP monoclonal antibody within 3 months prior to the start of the baseline period Prior/Concurrent Clinical Study Experience - Currently receiving treatment in another investigational device or drug study, or less than 30 days or 5 half-lives since ending treatment on another investigational device or drug study (ies). Other investigational procedures while participating in this study are excluded. Other Exclusions - Female subjects of childbearing potential with a positive pregnancy test assessed at screening or day 1 by a urine pregnancy test. - Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 16 weeks after the last dose of investigational product. - Female subjects of childbearing potential unwilling to use 1 acceptable method of effective contraception during treatment and for an additional 16 weeks after the last dose of investigational product. - Evidence of current pregnancy or breastfeeding per subject self-report or medical records - Subject has known sensitivity to any of the products or components to be administered during dosing - Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge Contraindications to MRI: - Does not wish to be informed about unexpected MRI findings - Severe claustrophobia - Implanted magnetic material including pacemaker, prothesis, metal-clips, etc. - Insulin pump which cannot be removed - Magnetic foreign object in the body - Surgical intervention within 6 weeks prior to MRI |
Country | Name | City | State |
---|---|---|---|
Denmark | Danish Headache Center | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Danish Headache Center |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Headache Diary | Headache diary with daily entries to record migraine-related data. | Baseline Phase (Day -42 to -28) to Month 6] | |
Secondary | 3T Brain Structural and Functional Magnetic Resonance Imaging (MRI) at Baseline | MP2RAGE GRAPPATINI Gradient-Recalled-Echo (GRE) Sequence w/wo Magnetization Transfer (MT) MPRAGE Diffusion Tensor Imaging (DTI) Resting State Functional MRI Task-Based Functional MRI (visual stimulation with checkerboard) 3D FLAIR |
Baseline Phase (Day -42 to -28) | |
Secondary | 3T Brain Structural and Functional Magnetic Resonance Imaging (MRI) at Baseline at Month 6 | MP2RAGE GRAPPATINI Gradient-Recalled-Echo (GRE) Sequence w/wo Magnetization Transfer (MT) MPRAGE Diffusion Tensor Imaging (DTI) Resting State Functional MRI Task-Based Functional MRI (visual stimulation with checkerboard) 3D FLAIR |
Week 24 ± 2 Weeks | |
Secondary | 3T Brain Structural and Functional Magnetic Resonance Imaging (MRI) at Baseline at Month 12 | MP2RAGE GRAPPATINI Gradient-Recalled-Echo (GRE) Sequence w/wo Magnetization Transfer (MT) MPRAGE Diffusion Tensor Imaging (DTI) Resting State Functional MRI Task-Based Functional MRI (visual stimulation with checkerboard) 3D FLAIR |
Week 48 ± 4 Weeks | |
Secondary | Headache Diary | Headache diary with daily entries to record migraine-related data. | Baseline Phase (Day -42 to -28) to Month 12 | |
Secondary | Blood Specimen for Analysis of Biomarkers at Baseline | 31 mL Blood for Plasma 16 mL Blood for Serum 28 mL Blood for Heparinized Plasma |
Baseline Phase (Day -42 to -28) | |
Secondary | Blood Specimen for Analysis of Biomarkers at Month 6 | 31 mL Blood for Plasma 16 mL Blood for Serum 28 mL Blood for Heparinized Plasma |
Week 24 ± 2 Weeks | |
Secondary | Blood Specimen for Analysis of Biomarkers at Month 12 | 31 mL Blood for Plasma 16 mL Blood for Serum 28 mL Blood for Heparinized Plasma |
Week 48 ± 4 Weeks | |
Secondary | Semi-Structured Interview | In-person semi-structured interview to record migraine-related data. | Baseline Phase (Day -42 to -28) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |